Canada markets closed

Protagenic Therapeutics, Inc. (PTIX)

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
Add to watchlist
1.3850-0.0650 (-4.48%)
At close: 04:00PM EDT
Currency in USD

Valuation Measures4

Market Cap (intraday) 6.14M
Enterprise Value 1.29M
Trailing P/E N/A
Forward P/E N/A
PEG Ratio (5 yr expected) N/A
Price/Sales (ttm)N/A
Price/Book (mrq)1.67
Enterprise Value/Revenue N/A
Enterprise Value/EBITDA -0.27

Trading Information

Stock Price History

Beta (5Y Monthly) 0.38
52-Week Change 3-26.33%
S&P500 52-Week Change 322.36%
52 Week High 32.3200
52 Week Low 30.6800
50-Day Moving Average 31.3099
200-Day Moving Average 31.2815

Share Statistics

Avg Vol (3 month) 311.82k
Avg Vol (10 day) 312.81k
Shares Outstanding 54.44M
Implied Shares Outstanding 64.44M
Float 83.22M
% Held by Insiders 121.83%
% Held by Institutions 17.96%
Shares Short (Apr 15, 2024) 49.83k
Short Ratio (Apr 15, 2024) 40.65
Short % of Float (Apr 15, 2024) 40.27%
Short % of Shares Outstanding (Apr 15, 2024) 40.22%
Shares Short (prior month Mar 15, 2024) 412.22k

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 30.00
Trailing Annual Dividend Yield 30.00%
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3Jul 27, 2016
Ex-Dividend Date 4N/A
Last Split Factor 21:4
Last Split Date 3Mar 23, 2023

Financial Highlights

Fiscal Year

Fiscal Year Ends Dec 31, 2023
Most Recent Quarter (mrq)Dec 31, 2023

Profitability

Profit Margin 0.00%
Operating Margin (ttm)0.00%

Management Effectiveness

Return on Assets (ttm)-45.78%
Return on Equity (ttm)-94.48%

Income Statement

Revenue (ttm)N/A
Revenue Per Share (ttm)N/A
Quarterly Revenue Growth (yoy)N/A
Gross Profit (ttm)N/A
EBITDA -4.5M
Net Income Avi to Common (ttm)-5M
Diluted EPS (ttm)-1.1500
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)4.06M
Total Cash Per Share (mrq)0.92
Total Debt (mrq)N/A
Total Debt/Equity (mrq)N/A
Current Ratio (mrq)6.41
Book Value Per Share (mrq)0.83

Cash Flow Statement

Operating Cash Flow (ttm)-3.7M
Levered Free Cash Flow (ttm)-2.47M